Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in bringing ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...

Enlaza's War-Lock platform uses covalent-acting protein drugs with non-natural amino acids, enhancing therapeutic windows for safer, effective treatments. The partnership targets autoimmune diseases ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including federal ...

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis (CF) ...

Feb 10 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and early ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain medicine in the US in more than 20 years. The oral NaV1.8 inhibitor has been ...

Dec 4 (Reuters) - The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals (VRTX.O), opens new tab and bluebird bio (BLUE.O), opens new ...